• PDF: Delivered by email usually within 48 UK business hours.

AVEO Pharmaceuticals, Inc. (AVEO) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:65

AVEO Pharmaceuticals, Inc. (AVEO) - Pharmaceuticals & Healthcare Deals and Alliances Profile

AVEO Pharmaceuticals, Inc. (AVEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

AVEO Pharmaceuticals, Inc. (Aveo) is a pharmaceutical company. It is principally engaged in the discovery and development of therapeutics against breast cancer, multiple myeloma and lung cancer. The company's product pipeline includes, Tivozanib (AV-951), an inhibitor of VEGF receptors 1, 2 and 3, currently in Phase 1b/2a clinical trial, for the treatment of metastatic breast cancer, non-small cell lung cancer, and renal cell cancer; AV-299, an anti-HGF monoclonal antibody, currently in Phase I clinical trial for the treatment of refractory tumors or lymphoma; and AV-203 is an ErbB3 antibody currently in preclinical studies for tumor of breast, ovarian, prostate, colorectal, pancreatic, gastric, and head and neck cancers. AVEO Pharmaceuticals, Inc. was previously known as GenPath Pharmaceuticals, Inc. The company is headquartered in Cambridge, the US.

AVEO Pharmaceuticals, Inc. (AVEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.
  • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
    • Venture Financing
    • Aveo Pharmaceuticals Secures $30 Million In Venture Financing
    • AVEO Pharmaceuticals Secures $43 Million in Series D Financing
    • Partnerships
    • Laureate Pharma Enters Into Co-Development Agreement With AVEO Pharmaceutical
    • OSI Pharmaceuticals Expands Research Collaboration With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Into Co-Development Agreement With Biogen Idec
    • OSI Pharmaceutical Enters Into Research Agreement With AVEO Pharmaceutical
    • Merck Enters Into Co-Development Agreement With AVEO Pharmaceuticals
    • Licensing Agreements
    • Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals For Tivozanib
    • OSI Pharmaceuticals Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • Dyax Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • GeneGo Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Lincensing Agreement With Peptech
    • AVEO Enters Into Licensing Agreement With Schering-Plough
    • AVEO Pharmaceuticals Enters Into Licensing Agreement With Kirin Brewery
    • XOMA Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Into A Licensing Agreeement With Mitsubishi Pharma
    • Equity Offering
    • AVEO Pharmaceuticals Announces Private Placement Of $61 Million
    • AVEO Pharmaceuticals Completes IPO Of $90 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $5.5 Million
    • Debt Offering
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Recent Developments
    • Financial Announcements
    • Jul 29, 2010: AVEO Reports Net Loss Of $15.5 Million For Q2 2010
    • Jul 29, 2010: AVEO Reports Net Loss Of $15.5 Million For Q2 2010
    • Apr 29, 2010: AVEO Reports Net Loss Of $14.4 Million For Q1 2010
    • Corporate Communications
    • Sep 13, 2010: AVEO Pharmaceuticals Appoints Michael Bailey As Chief Commercial Officer
    • Sep 16, 2009: AVEO Appoints William Slichenmyer As CEO And Robert Young To Board
    • Product News
    • Nov 19, 2010: AVEO Preports Preclinical Data From Anti-RON Monoclonal Antibody Program At EORTC-NCI-AACR Symposium
    • Nov 06, 2007: Results From Phase 1 Study Of Aveo's Novel Triple Vegf Receptor Inhibitor Av-951
    • Oct 29, 2003: Genpath Pharmaceuticals Announces Issuance Of Fundamental U.S. Patent Covering Its Proprietary Cancer Models
    • Aug 25, 2008: Aveo Initiates Phase 1b Combination Trial Of Av-951
    • Jul 31, 2009: Preclinical Data Presented At International Lung Conference; Underscores Tivozanib Potency
    • Jul 08, 2009: Aveo Pharmaceuticals Granted Patent For Protection Of Its Directed Complementation Technology
    • Jun 17, 2009: Aveo Pharmaceuticals Granted Patent For Predictive Biomarker Used To Identify Human Tumors Likely To Respond To Notch Pathway Inhibition
    • May 29, 2009: Av-951 Demonstrates Prolonged Progression-Free Survival And Excellent Safety Profile In Patients With Advanced Kidney Cancer; Phase 2 Data Presented At Asco
    • May 22, 2008: Aveo Pharmaceuticals Granted Patent For Unique Genetic Screen To Identify Novel Cancer Drug Targets
    • Apr 21, 2010: AVEO's Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity
    • Apr 21, 2010: AVEO's Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory Activity
    • Apr 21, 2009: Aveo Announces Positive Finding For Triple Vegf Receptor Inhibitor Av-951 In Preclinical Model Of Liver Cancer
    • Apr 19, 2009: Aveo Presents Promising Preclinical Activity To Support Antibody Agent Sch 900105 (Av-299)
    • Apr 18, 2007: Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
    • Apr 14, 2008: Aveo Pharmaceuticals' Novel Triple Vegf Receptor Inhibitor Shows Tumor Regression In Patients With Advanced Renal Cancer; Clinical Activity And Tolerability In Other Solid Tumors Including Colon And Lung Cancers
    • Apr 09, 2009: Data From Aveos Av-951 In Liver Cancer Model And Preclinical Activity In Sch 900105 (Av-299) To Be Presented At Aacr Annual Meeting
    • Apr 06, 2009: Breakthrough Preclinical Model For Human Cancer May Dramatically Improve Development Of Effective Oncology Drugs; Data Published In Pnas
    • Apr 04, 2006: Av-412 Preclinical Efficacy Data Presented At Aacr 2006
    • Feb 25, 2009: Aveos Oral Triple Vegf Receptor Inhibitor Av-951 Shows Robust Activity In Patients With Advanced Kidney Cancer
    • Feb 11, 2009: Aveo Announces Oral Presentation Of Data From Av-951 Phase 2 Clinical Trial At The 2009 Genitourinary Symposium
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 65
  • List of Tables
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2009
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Deals By Therapy Area, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Aveo Pharmaceuticals Secures $30 Million In Venture Financing
    • AVEO Pharmaceuticals Secures $43 Million in Series D Financing
    • Laureate Pharma Enters Into Co-Development Agreement With AVEO Pharmaceutical
    • OSI Pharmaceuticals Expands Research Collaboration With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Into Co-Development Agreement With Biogen Idec
    • OSI Pharmaceutical Enters Into Research Agreement With AVEO Pharmaceutical
    • Merck Enters Into Co-Development Agreement With AVEO Pharmaceuticals
    • Astellas Pharma Enters Into Licensing Agreement With AVEO Pharmaceuticals For Tivozanib
    • OSI Pharmaceuticals Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • Dyax Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • GeneGo Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Lincensing Agreement With Peptech
    • AVEO Enters Into Licensing Agreement With Schering-Plough
    • AVEO Pharmaceuticals Enters Into Licensing Agreement With Kirin Brewery
    • XOMA Enters Into Licensing Agreement With AVEO Pharmaceuticals
    • AVEO Pharmaceuticals Enters Into A Licensing Agreeement With Mitsubishi Pharma
    • AVEO Pharmaceuticals Announces Private Placement Of $61 Million
    • AVEO Pharmaceuticals Completes IPO Of $90 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $5.5 Million
    • AVEO Pharmaceuticals Completes Private Placement Of $15 Million
    • AVEO Pharmaceuticals, Inc., Key Employees 45
  • List of Figures
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • AVEO Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about AVEO Pharmaceuticals, Inc. (AVEO) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha